Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$26.12
+$0.49 (+1.91%)
Nov 2, 2026, 9:55 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | 110K | n/a |
Gross Profit | -110K | n/a |
Operating Income | -59.2M | -27.91M |
Interest Income | 3.82M | 1.13M |
Pretax Income | -55.8M | -26.87M |
Net Income | -55.8M | -26.87M |
Selling & General & Admin | 11.47M | 5.02M |
Research & Development | 47.62M | 22.89M |
Other Expenses | n/a | n/a |
Operating Expenses | 59.09M | 27.91M |
Interest Expense | 370K | 98K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 59.2M | 27.91M |
Income Tax Expense | n/a | n/a |
Shares Outstanding (Basic) | 44.33M | 41.81M |
Shares Outstanding (Diluted) | 44.33M | 41.81M |
EPS (Basic) | -1.29 | -0.64 |
EPS (Diluted) | -1.29 | -0.64 |
EBITDA | -57.89M | -26.71M |
EBIT | -58.06M | -26.77M |
Depreciation & Amortization | 173K | 63K |
Add to Watchlist
Select watchlists to add or remove AVLN